| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $33,799,031 ) (Continued on the next page) |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 01 | 4 | HRSA | 6/15/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 00 | 4 | HRSA | 4/21/2026 | $398,872 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH127308 | Adaptation and assessment of a common element treatment protocol designed to improve mental health in forcibly displaced populations | 001 | 5 | NIH | 7/31/2026 | $32,516 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH127308 | Adaptation and assessment of a common element treatment protocol designed to improve mental health in forcibly displaced populations | 000 | 5 | NIH | 7/22/2026 | $150,731 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R13DA052198 | Substance Use Modeling Consortium Workshop to Support the Public Health Response to the Overdose Crisis in North America | 000 | 6 | NIH | 7/7/2026 | $24,512 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H1224845 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 04 | 13 | HRSA | 7/15/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H1224845 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 03 | 13 | HRSA | 6/23/2026 | $89,646 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA066715 | Evaluating the Health Impacts of Interventions to Address Homelessness and Opioid Use Disorder | 001 | 1 | NIH | 6/29/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA066715 | Evaluating the Health Impacts of Interventions to Address Homelessness and Opioid Use Disorder | 000 | 1 | NIH | 6/9/2026 | $796,649 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01MH138549 | Adaptive interventions to improve posttraumatic stress (PTSD) treatment access, engagement, and effectiveness in routine care | 000 | 2 | NIH | 7/15/2026 | $863,400 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD019068 | Adapting an Evidence-Based Intervention to Improve the Hospital Discharge Process for Patients with Limited English Proficiency | 002 | 4 | NIH | 7/14/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD019068 | Adapting an Evidence-Based Intervention to Improve the Hospital Discharge Process for Patients with Limited English Proficiency | 001 | 4 | NIH | 6/19/2026 | $162,202 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23AI186597 | The relationship between HIV exposure, contact networks, and TB in children under 5 years old | 000 | 3 | NIH | 7/22/2026 | $190,512 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | UT953486 | Supporting Fetal Alcohol Spectrum Disorders (FASD) Screening and Intervention | 00 | 3 | HRSA | 8/6/2026 | $980,553 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | U01DK133092 | Boston Chronic Kidney Disease Research Biopsy Center | 000 | 5 | NIH | 7/16/2026 | $799,999 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK138309 | Effectiveness Trial to Support Adoption of Hybrid Closed Loop Therapy in Underserved Adults with Type 1 Diabetes: Impact of System Functionality and Features on Lived Experience | 000 | 3 | NIH | 1/28/2026 | $844,525 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9E53185 | Transition for Youth with Autism and/or Epilepsy Demonstration Projects | 00 | 3 | HRSA | 7/24/2026 | $449,740 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD115574 | Efficacy of Teleconsultation to Improve Prehospital Patient Safety for Critically Ill Infants and Children - A Multicenter, Simulation-based Randomized Control Trial | 000 | 3 | NIH | 8/7/2026 | $746,787 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32MH135857 | Boston University Medical Campus- Massachusetts General Hospital Global Psychiatric Clinical Research Training Program | 000 | 3 | NIH | 6/23/2026 | $358,488 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an Inherent Bias in Neuroprognostication: A Collaboration Between the US and Brazil to Reduce the Impact of Self-Fulfilling Prophecy in Cardiac ARrEst (SPARE) | 001 | 3 | NIH | 2/27/2026 | $25,758 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an Inherent Bias in Neuroprognostication: A Collaboration Between the US and Brazil to Reduce the Impact of Self-Fulfilling Prophecy in Cardiac ARrEst (SPARE) | 000 | 3 | NIH | 2/20/2026 | $478,045 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an Inherent Bias in Neuroprognostication: A Collaboration Between the US and Brazil to Reduce the Impact of Self-Fulfilling Prophecy in Cardiac ARrEst (SPARE) | 004 | 3 | NIH | 3/4/2026 | $25,758 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an Inherent Bias in Neuroprognostication: A Collaboration Between the US and Brazil to Reduce the Impact of Self-Fulfilling Prophecy in Cardiac ARrEst (SPARE) | 003 | 3 | NIH | 3/3/2026 | $25,758 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an Inherent Bias in Neuroprognostication: A Collaboration Between the US and Brazil to Reduce the Impact of Self-Fulfilling Prophecy in Cardiac ARrEst (SPARE) | 002 | 3 | NIH | 3/2/2026 | $25,758 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T2554939 | Addiction Medicine Fellowship | 01 | 2 | HRSA | 6/30/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T2554939 | Addiction Medicine Fellowship | 00 | 2 | HRSA | 5/21/2026 | $799,517 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | M0154849 | Behavioral Health Workforce Education and Training Program | 00 | 2 | HRSA | 6/4/2026 | $599,853 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01DA052821 | Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV) | 000 | 5 | NIH | 7/10/2026 | $189,216 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 001 | 3 | NIH | 3/13/2026 | $23,581 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 000 | 3 | NIH | 3/9/2026 | $746,783 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166608 | Disease-specific risk factors for thrombosis following vascular interventions | 000 | 4 | NIH | 7/30/2026 | $660,794 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08DA058052 | Impact of initial buprenorphine prescribing strategies on retention in care for patients with opioid use disorder | 001 | 4 | NIH | 7/31/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08DA058052 | Impact of initial buprenorphine prescribing strategies on retention in care for patients with opioid use disorder | 000 | 4 | NIH | 4/27/2026 | $185,085 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D4054828 | Graduate Psychology Education Programs | 01 | 2 | HRSA | 6/23/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D4054828 | Graduate Psychology Education Programs | 00 | 2 | HRSA | 5/28/2026 | $449,972 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA058367 | PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | 000 | 4 | NIH | 7/6/2026 | $1,068,172 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD113143 | Association of maternal, fetal and placental biomarkers with neonatal neuroimaging and development following in-utero opioid exposure | 000 | 2 | NIH | 8/6/2026 | $834,420 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 000 | 3 | NIH | 8/11/2026 | $165,349 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 000 | 3 | NIH | 8/11/2026 | $344,666 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 000 | 5 | NIH | 1/22/2026 | $414,060 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 001 | 5 | NIH | 7/14/2026 | $172,325 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 000 | 5 | NIH | 7/1/2026 | $520,034 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133404 | Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | 000 | 5 | NIH | 4/3/2026 | $577,631 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK118267 | Nucleophosmin Centered Diagnostics and Treatment of Ischemic Acute Kidney Injury | 000 | 7 | NIH | 3/24/2026 | $555,038 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL178832 | Niche-specific endothelial mechanisms regulating the extravasation of hematopoietic stem cells | 001 | 2 | NIH | 3/24/2026 | $21,594 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL178832 | Niche-specific endothelial mechanisms regulating the extravasation of hematopoietic stem cells | 000 | 2 | NIH | 2/24/2026 | $683,816 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK142896 | The Impact of Allostatic Load on Kidney Disease | 000 | 1 | NIH | 7/7/2026 | $918,576 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R13DA064395 | Academic Consortium of Criminal Justice Health | 000 | 2 | NIH | 5/25/2026 | $77,200 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03CA308637 | Personalized Spatial Regulatory Networks to Decode Breast Cancer Microenvironments | 000 | 1 | NIH | 6/12/2026 | $178,000 |
|
